PDCA循環(huán)法在處方點(diǎn)評(píng)中的應(yīng)用分析
【摘要】目的:研究分析西藥在處方點(diǎn)評(píng)中使用PDCA循環(huán)法的應(yīng)用價(jià)值。方法:對(duì)我院2000張西藥處方開(kāi)展調(diào)查,2021年1月—2021年12月之間實(shí)施處方點(diǎn)評(píng),視為對(duì)照組;2022年1月—2022年12月之間聯(lián)合處方點(diǎn)評(píng)開(kāi)展PDCA循環(huán)法,視為觀察組。對(duì)比兩組分析結(jié)果。結(jié)果:兩組處方不合理主要表現(xiàn)在無(wú)用藥指征、重復(fù)用藥、用法用量不合理、聯(lián)合用藥不合理等方面,觀察組不合理處方率明顯低于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P
【關(guān)鍵詞】PDCA循環(huán)法;處方點(diǎn)評(píng);處方質(zhì)量;合理用藥
Application and Analysis of PDCA Cycle Method in Prescription Evaluation
HAN Na
Gansu Dingxi Longxi County Maternal and Child Health Care Hospital, Dingxi, Gansu 748400, China
【Abstract】Objective:To study and analyze the application value of PDCA circulation method in prescription evaluation of western drugs.Methods:A survey was conducted on 2000 prescriptions of Western medicine in our hospital.From January 2021 to December 2021,prescription review was conducted,which was regarded as the control group;From January 2022 to December 2022,the PDCA cycle method was used for joint prescription review,and which was considered as the observation group.The results of analysis between the two groups were compared.Results:Unreasonable prescriptions in the two groups were mainly manifested in useless drug indications,repeated medication,unreasonable usage and dosage,and unreasonable combination medication,the irrational rate of prescriptions in the observation group was lower than that in the control group,with a statistically significant difference (P
【Key Words】PDCA cycle method; Prescription review; Prescription quality; Rational use
處方為用藥憑證,研究指出處方質(zhì)量能夠在一定程度上代表一家醫(yī)院的總體醫(yī)療水平,更重要的是,處方合理性直接決定了用藥合理性,處方不合理會(huì)直接影響到處方總體療效與安全性。(剩余4361字)
- 婚檢和孕前檢查人群中的梅毒臨床...
- 小劑量米索前列醇用于足月妊娠促...
- 彩色多普勒超聲在乳腺惡性腫瘤診...
- 腹腔鏡聯(lián)合地諾孕素治療中、重度...
- 導(dǎo)管周?chē)橄傺椎牟∫蚝椭委熝芯?..
- 基于Teach-back模式的...
- PDCA循環(huán)法在處方點(diǎn)評(píng)中的應(yīng)...
- 布地奈德、沙丁胺醇、異丙托溴銨...
- 單側(cè)大腦中動(dòng)脈病變患者側(cè)支循環(huán)...
- 雙鏡聯(lián)合膽總管切開(kāi)取石膽管無(wú)支...
- 右美托咪定作為佐劑的豎脊肌平面...
- 纈沙坦聯(lián)合氨氯地平在農(nóng)村老年原...
- 不同劑量他汀治療腔隙性腦梗死的...
- 含鉍四聯(lián)療法聯(lián)合雙歧桿菌四聯(lián)活...
- 注射用益氣復(fù)脈聯(lián)合環(huán)磷腺苷注射...
- 干擾素霧化治療對(duì)呼吸道合胞病毒...
- 靜脈用藥調(diào)配中心抗腫瘤藥物配置...
- 烏雞白鳳丸治療女大學(xué)生原發(fā)性痛...
- 中醫(yī)美容在痤瘡患者中的應(yīng)用...
- 柴胡疏肝散合左金丸加味治療膽汁...
- 中藥灌腸治療慢性腎衰竭的臨床觀...
- 綜合護(hù)理聯(lián)合中藥熏洗在肛周膿腫...
- 中藥熱奄包在心衰合并便秘患者治...
- 強(qiáng)化健康教育對(duì)小兒哮喘相關(guān)癥狀...
- 心理護(hù)理在小兒靜脈輸液護(hù)理中的...
- 生理性海水鼻噴劑對(duì)兒童過(guò)敏性鼻...
- 中樞性性早熟和單純?nèi)榉吭绨l(fā)育之...
- 優(yōu)質(zhì)護(hù)理服務(wù)在產(chǎn)科護(hù)理中的應(yīng)用...
- 分析二次剖宮產(chǎn)的護(hù)理措施及護(hù)理...
- 個(gè)性化護(hù)理干預(yù)對(duì)妊娠期糖尿病患...
- 心理護(hù)理聯(lián)合微課健康教育預(yù)防產(chǎn)...
- 護(hù)理質(zhì)量持續(xù)改進(jìn)在子宮肌瘤護(hù)理...
- 心肺康復(fù)運(yùn)動(dòng)處方在心臟瓣膜置換...
- 延續(xù)性護(hù)理對(duì)乳腺癌術(shù)后患者肩關(guān)...
- MDT護(hù)理模式在結(jié)腸癌患者圍術(shù)...
- 糖尿病腎病所致尿毒癥患者行維持...
- 循證護(hù)理對(duì)改善膽囊結(jié)石病患者術(shù)...
- 食道早癌內(nèi)鏡下黏膜剝離術(shù)的護(hù)理...
- 集束化護(hù)理預(yù)防腦出血患者術(shù)后下...
- 胃出血患者內(nèi)鏡輔助治療的有效護(hù)...
- 快速康復(fù)護(hù)理對(duì)粘連性腸梗阻患者...
- 口腔黏膜炎分級(jí)個(gè)性化護(hù)理在鼻咽...
- 心理護(hù)理聯(lián)合預(yù)見(jiàn)性護(hù)理在上消化...
- 臨床護(hù)理路徑在頭頸部惡性腫瘤患...
- 責(zé)任制整理護(hù)理在維持性血液透析...
- 心理干預(yù)對(duì)獻(xiàn)血者血液報(bào)廢率、心...
- 1例基于敘事護(hù)理策略解決心尖肥...
- 復(fù)雜性視網(wǎng)膜脫離患者術(shù)后疼痛的...
- 基于優(yōu)質(zhì)服務(wù)理念的護(hù)理策略對(duì)C...
- 針對(duì)性護(hù)理干預(yù)對(duì)腦外傷術(shù)后患者...
- 全方位護(hù)理干預(yù)在心力衰竭合并呼...
- 早期康復(fù)護(hù)理對(duì)心血管內(nèi)科護(hù)理不...
- 細(xì)節(jié)護(hù)理聯(lián)合心理干預(yù)對(duì)慢性扁桃...
- 預(yù)見(jiàn)性護(hù)理管理在腎結(jié)石術(shù)后尿路...
- 以活動(dòng)性疼痛護(hù)理評(píng)估為基礎(chǔ)的疼...
- 保護(hù)動(dòng)機(jī)理論在腦卒中患者康復(fù)護(hù)...
- 探討急診觀察室實(shí)施整體護(hù)理措施...
- 手術(shù)室綜合護(hù)理對(duì)人工全膝關(guān)節(jié)置...
- 綜合護(hù)理干預(yù)對(duì)慢性腎功能衰竭血...
- 預(yù)見(jiàn)性護(hù)理在肺結(jié)核合并大咯血患...
- 階段性康復(fù)護(hù)理對(duì)腹腔鏡肝癌切除...
- 外來(lái)醫(yī)療器械處理過(guò)程中的難點(diǎn)與...
- 護(hù)患溝通在高血壓護(hù)理過(guò)程中的作...
- 舒適護(hù)理干預(yù)在老年慢性心衰護(hù)理...
- 延續(xù)性護(hù)理對(duì)人工髖關(guān)節(jié)置換術(shù)后...
- 早期康復(fù)護(hù)理對(duì)顱腦外傷術(shù)后運(yùn)動(dòng)...